Sclafani, Francesco
Royal Marsden Hospital
3 papers on CoChatORCID 0000-0003-0251-2627
Most cited papers
- Verified
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer
Woolston, A., Khan, K., Spain, G., Barber, L. J., Griffiths, B., Gonzalez-Exposito, R., Hornsteiner, L., Punta, M., Patil, Y., Newey, A., et al. (2019) · Cancer Cell
Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers
Cited by 254
- Verified
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory,KRAS Wild-Type, Metastatic Colorectal Cancer
Sclafani, F., Kim, T. Y., Cunningham, D., Kim, T. W., Tabernero, J., Schmoll, H. J., Roh, J. K., Kim, S. Y., Park, Y. S., Guren, T. K., et al. (2015) · Journal of the National Cancer Institute
Colorectal Cancer Treatments and StudiesGrowth Hormone and Insulin-like Growth Factors
Cited by 92
- Verified
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab
Sclafani, F., Roy, A., Cunningham, D., Wotherspoon, A., Peckitt, C., Gonzalez de Castro, D., Tabernero, J., Glimelius, B., Cervantes, A., Eltahir, Z., et al. (2013) · Annals of Oncology
Colorectal Cancer Surgical TreatmentsHER2/EGFR in Cancer Research
Cited by 33
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free